Literature DB >> 25569455

Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC.

Megan M Romeo1, Bookyung Ko1, Janice Kim1, Rebecca Brady1, Hayley C Heatley1, Jeffrey He1, Carolyn K Harrod1, Braden Barnett1, Lee Ratner2, Michael D Lairmore3, Ernest Martinez4, Bernhard Lüscher5, Craig N Robson6, Marie Henriksson7, Robert Harrod8.   

Abstract

The human T-cell leukemia retrovirus type-1 (HTLV-1) p30(II) protein is a multifunctional latency-maintenance factor that negatively regulates viral gene expression and deregulates host signaling pathways involved in aberrant T-cell growth and proliferation. We have previously demonstrated that p30(II) interacts with the c-MYC oncoprotein and enhances c-MYC-dependent transcriptional and oncogenic functions. However, the molecular and biochemical events that mediate the cooperation between p30(II) and c-MYC remain to be completely understood. Herein we demonstrate that p30(II) induces lysine-acetylation of the c-MYC oncoprotein. Acetylation-defective c-MYC LysArg substitution mutants are impaired for oncogenic transformation with p30(II) in c-myc(-/-) HO15.19 fibroblasts. Using dual-chromatin-immunoprecipitations (dual-ChIPs), we further demonstrate that p30(II) is present in c-MYC-containing nucleoprotein complexes in HTLV-1-transformed HuT-102 T-lymphocytes. Moreover, p30(II) inhibits apoptosis in proliferating cells expressing c-MYC under conditions of genotoxic stress. These findings suggest that c-MYC-acetylation is required for the cooperation between p30(II)/c-MYC which could promote proviral replication and contribute to HTLV-1-induced carcinogenesis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetylation; Apoptosis; HTLV-1; Transformation; c-MYC; p30

Mesh:

Substances:

Year:  2015        PMID: 25569455      PMCID: PMC4323988          DOI: 10.1016/j.virol.2014.12.008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  97 in total

1.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter.

Authors:  C Bouchard; O Dittrich; A Kiermaier; K Dohmann; A Menkel; M Eilers; B Lüscher
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

Review 2.  Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins.

Authors:  Nancy Van Prooyen; Vibeke Andresen; Heather Gold; Izabela Bialuk; Cynthia Pise-Masison; Genoveffa Franchini
Journal:  Mol Aspects Med       Date:  2010-07-29

3.  Histone acetyltransferase (HAT) activity of p300 modulates human T lymphotropic virus type 1 p30II-mediated repression of LTR transcriptional activity.

Authors:  Bindhu Michael; Amrithraj M Nair; Antara Datta; Hajime Hiraragi; Lee Ratner; Michael D Lairmore
Journal:  Virology       Date:  2006-08-04       Impact factor: 3.616

4.  Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines.

Authors:  A Cereseto; Z Berneman; I Koralnik; J Vaughn; G Franchini; M E Klotman
Journal:  Leukemia       Date:  1997-06       Impact factor: 11.528

5.  Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300.

Authors:  W Zhang; J W Nisbet; B Albrecht; W Ding; F Kashanchi; J T Bartoe; M D Lairmore
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Distinct p300-responsive mechanisms promote caspase-dependent apoptosis by human T-cell lymphotropic virus type 1 Tax protein.

Authors:  C Nicot; R Harrod
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

7.  Cooperative effects of genes controlling the G(2)/M checkpoint.

Authors:  T A Chan; P M Hwang; H Hermeking; K W Kinzler; B Vogelstein
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

8.  The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60.

Authors:  Jagruti H Patel; Yanping Du; Penny G Ard; Charles Phillips; Beth Carella; Chi-Ju Chen; Carrie Rakowski; Chandrima Chatterjee; Paul M Lieberman; William S Lane; Gerd A Blobel; Steven B McMahon
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation.

Authors:  Joshua Arnold; Bevin Zimmerman; Min Li; Michael D Lairmore; Patrick L Green
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

10.  HTLV-1 HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT).

Authors:  Anne-Sophie Kuhlmann; Julien Villaudy; Louis Gazzolo; Marc Castellazzi; Jean-Michel Mesnard; Madeleine Duc Dodon
Journal:  Retrovirology       Date:  2007-12-13       Impact factor: 4.602

View more
  6 in total

1.  The human T-cell leukemia virus type-1 tax oncoprotein dissociates NF-κB p65RelA-Stathmin complexes and causes catastrophic mitotic spindle damage and genomic instability.

Authors:  Aditi Malu; Tetiana Hutchison; Laçin Yapindi; Katie Smith; Katherine Nelson; Rachel Bergeson; Jordan Pope; Megan Romeo; Carolyn Harrod; Lee Ratner; Carine Van Lint; Robert Harrod
Journal:  Virology       Date:  2019-07-03       Impact factor: 3.616

2.  The human T-cell leukemia virus type-1 p30II protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis.

Authors:  Megan Romeo; Tetiana Hutchison; Aditi Malu; Averi White; Janice Kim; Rachel Gardner; Katie Smith; Katherine Nelson; Rachel Bergeson; Ryan McKee; Carolyn Harrod; Lee Ratner; Bernhard Lüscher; Ernest Martinez; Robert Harrod
Journal:  Virology       Date:  2018-02-20       Impact factor: 3.616

Review 3.  How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?

Authors:  Charles R M Bangham; Lee Ratner
Journal:  Curr Opin Virol       Date:  2015-09-27       Impact factor: 7.090

Review 4.  MiR-150 in HTLV-1 infection and T-cell transformation.

Authors:  Donna M D'Agostino; Vittoria Raimondi; Micol Silic-Benussi; Vincenzo Ciminale
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

Review 5.  Metabolite-derived protein modifications modulating oncogenic signaling.

Authors:  Yawen Liu; Anke Vandekeere; Min Xu; Sarah-Maria Fendt; Patricia Altea-Manzano
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

Review 6.  Silencers of HTLV-1 and HTLV-2: the pX-encoded latency-maintenance factors.

Authors:  Robert Harrod
Journal:  Retrovirology       Date:  2019-09-06       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.